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Abstract
Background Osteoarthritis (OA) is a chronic joint disease, with increasing global burden of disability and healthcare utilisa-
tion. Recent meta-analyses have shown a range of effects of OA on mortality, reflecting different OA definitions and study 
methods. We seek to overcome limitations introduced when using aggregate results by gathering individual participant-level 
data (IPD) from international observational studies and standardising methods to determine the association of knee OA with 
mortality in the general population.
Methods Seven community-based cohorts were identified containing knee OA-related pain, radiographs, and time-to-mor-
tality, six of which were available for analysis. A two-stage IPD meta-analysis framework was applied: (1) Cox proportional 
hazard models assessed time-to-mortality of participants with radiographic OA (ROA), OA-related pain (POA), and a com-
bination of pain and ROA (PROA) against pain and ROA-free participants; (2) hazard ratios (HR) were then pooled using 
the Hartung–Knapp modification for random-effects meta-analysis.
Findings 10,723 participants in six cohorts from four countries were included in the analyses. Multivariable models (adjust-
ing for age, sex, race, BMI, smoking, alcohol consumption, cardiovascular disease, and diabetes) showed a pooled HR, 
compared to pain and ROA-free participants, of 1.03 (0.83, 1.28) for ROA, 1.35 (1.12, 1.63) for POA, and 1.37 (1.22, 1.54) 
for PROA.
Discussion Participants with POA or PROA had a 35–37% increased association with reduced time-to-mortality, independ-
ent of confounders. ROA showed no association with mortality, suggesting that OA-related knee pain may be driving the 
association with time-to-mortality.
Funding Versus Arthritis Centre for Sport, Exercise and Osteoarthritis and Osteoarthritis Research Society International.
Keywords Osteoarthritis · Knee · Mortality · Meta-analysis
Introduction
The prevalence of musculoskeletal disorders (not including 
back pain) was ranked 19th for men and 20th for women in 
the 2017 Global Burden of Disease study. Knee OA made 
up 20% of this musculoskeletal burden. In terms of living 
with disability, musculoskeletal disorders ranked 10th and 
11th for men and women, respectively [1]. The lifetime risk 
of knee osteoarthritis is estimated to be 45% [2], and the 
prevalence of knee OA is expected to rise in accordance with 
the increase in the ageing population and obesity epidemic 
in many parts of the world.
OA is a common debilitating joint disease, frequently 
associated with joint pain, functional limitation, and 
decreased quality of life [3]. It most commonly affects the 
knees, hips, hands, facet joints, and feet [4], with knee and 
hip OA causing the greatest burden to the population, as 
The members of The PCCOA Steering Committee are listed in 
“Acknowledgements” section.
 * Nigel K. Arden 
 nigel.arden@ndorms.ox.ac.uk
Extended author information available on the last page of the article
530 Aging Clinical and Experimental Research (2021) 33:529–545
1 3
pain and stiffness in these large weight-bearing joints often 
lead to significant physical dysfunction such as knee muscle 
weakness and limited flexion [5].
Since 2008, ten studies and three meta-analyses have 
reported the association between knee OA and mortality, 
with only a handful of studies before this time [6–9]. Var-
ied findings of both positive and negative associations have 
made it difficult to draw conclusions regarding the effects of 
OA on mortality [8, 10–16].
This variation in findings reflects differences in popula-
tions studied (clinical or general), the diagnostic methods 
used to define OA, statistical methodology used, and the 
use or inclusion of important confounders in each study. 
Traditional meta-analyses are valuable and efficient in terms 
of time and resources required, but do have several limita-
tions, which have been widely recognised [17–19] includ-
ing reliance by necessity on published data increasing the 
potential for publication bias as negative studies difficult 
to publish. Aggregate data are often not available, poorly 
reported, derived, and presented differently across studies 
(for example, odds ratio versus relative risk), and most stud-
ies vary in their definitions of exposures, confounders and 
outcomes [20].
Individual patient-level (IPD) meta-analysis utilises orig-
inal raw data from cohorts and uses standardised statisti-
cal methods to analyse and produce pooled estimates [21]. 
IPD meta-analysis, although time-consuming and resource 
intensive, does not depend on previously published data, 
allows for a standardised definition of important variables 
and can be analysed using the same statistical approach. 
Within the current study, key measures of OA and relevant 
confounders are harmonised (based on expert consensus) 
[22], and consistent methods of analyses are used between 
cohorts to provide a more generalizable estimate of the asso-
ciation between OA and premature mortality in the general 
population.
This study seeks to overcome the limitations introduced 
when using aggregated results by gathering and analysing 
individual participant-level data from multiple interna-
tional observational osteoarthritis cohort studies to describe 




This study was designed to assess the relationship between 
knee osteoarthritis and time-to all-cause-mortality in mul-
tiple, prospective, longitudinal, community-based cohort 
studies from around the world. Subjects were stratified by 
the presence or absence of osteoarthritis at baseline, and 
time-to-mortality was compared between groups. Pooled 
estimates were produced using a two-stage individual par-
ticipant-level meta-analysis framework consisting of two 
discrete steps: (1) analysing the individual cohorts sepa-
rately; and (2) applying traditional meta-analysis methods 
to produce a pooled effect size [21].
A two-stage analysis can more easily handle cohort-spe-
cific characteristics such as heterogeneous populations, dif-
ferent risk relationships (such as direction and shape), and 
the effect of confounders, and can more overtly handle both 
sporadic and systematic missing data, unlike a one-stage 
analysis (i.e., pooling all data) [23]. A two-stage analysis 
allows for consistently defining the primary risk factors, 
outcome variables, adjusting for the same confounders, and 
using consistent statistical methods before producing a sin-
gle pooled effect size. Unlike a traditional meta-analysis, it 
also allows for the inclusion of previously unpublished data.
Cohort and participant inclusion/exclusion criteria
Due to the type of data required (detailed pain and radio-
graphic data), and the desire to use cohorts, including those 
which had not been previously published on the OA/mortal-
ity relationship, we identified cohorts using two sources: (1) 
published literature of cohort studies on knee osteoarthritis 
and mortality; and (2) contacting principal investigators of 
longitudinal osteoarthritis cohorts to see whether mortality 
data had been collected. We did not conduct a traditional 
systematic review, and as evidenced by the three recent sys-
tematic reviews and meta-analyses, several of the cohorts we 
have included in our study would not have been identified 
[7–9].
The inclusion criteria for cohorts were: (1) OA-related 
knee pain and knee radiographic data available at baseline 
for both OA and non-OA subjects; (2) time-to-mortality 
follow-up data for all participants; and (3) recruitment from 
the community (i.e., not identified through clinics, hospi-
tals, or healthcare professionals). Exclusion criteria were: (1) 
cohorts where raw data could not be released for analysis; 
and (2) data not available for both OA and non-OA subjects. 
Cohorts were not selected with regard to previously pub-
lished data on the relationship between OA and mortality.
We identified 40 cohorts via the two previously described 
sources as potentially having knee osteoarthritis data from 
the general population. Eighteen were excluded due to being 
a non-observational cohort or non-community-based or a 
case–control study. Thirteen lacked the appropriate knee 
X-ray or pain data at baseline after more detailed investi-
gation, and two lacked available mortality or time-to-death 
data. Seven potentially eligible cohorts were identified, one 
of which had data access limitations, leaving six cohort 
studies available for analysis (see flow chart, Appendix 1). 
The six cohorts included were: three US community-based 
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cohorts (Framingham and Johnston County Osteoarthritis 
Project) [24, 25], one of which was enhanced for OA risk 
factors [Multicentre Osteoarthritis Study (MOST)] [26]; one 
community-based cohort from the United Kingdom (Ching-
ford) [27]; one Chinese community-based cohort (Wuchuan) 
[28]; and one Australian community-based cohort [The Tas-
manian Older Adult Cohort (TasOAC)] [29]. All cohorts 
provided data for all participants except Framingham which 
provided a random sample of 80%.
Key differences between cohorts (Appendix 2) are the 
year of baseline visit, length of follow-up, the baseline age 
of participants, and the lack of side-specific pain in a single 
cohort. Participants were included in the analysis if they 
were over 45 years of age, did not have evidence of rheuma-
toid arthritis, and had mortality data available. After initial 
data checks, subjects above the age of 80 were also excluded 
due to the extremely small numbers available (Appendix 2).
Data collection process
IPD was requested from the principle investigators of any 
identified cohort after submitting an analysis plan for their 
team to review. Principle investigators were also contacted 
directly in cases where data had never been previously 
released to outside research teams.
A subset of the full data containing only the pre-specified 
exposures, outcomes, and confounders was requested, trans-
ferred via encrypted online servers, and stored and managed 
centrally by the Oxford research team. A open email dia-
logue was maintained with principle investigators and key 
researchers from each cohort throughout the process of data 
acquisition, harmonisation, and analysis to ensure consist-
ency between cohorts.
Primary risk factor: knee osteoarthritis
Due to the importance of using a consistent definition of 
osteoarthritis to avoid misclassification, we gained expert 
opinion on methods to harmonise knee osteoarthritis vari-
ables in prospective OA cohort studies, and all OA criteria 
used in this analysis were defined following a process of 
expert consultation, analysis, and agreement [22]. The key 
output of this meeting supported the use of both a binary 
self-reported pain question and the presence of radiographic 
OA to define knee OA in the general population. Thus, knee 
pain was defined using either an NHANES-type question 
(i.e., ‘have you had pain for at least a month in the last 
month in your joint’), or a similar alternative pain question 
if an NHANES-type question had not been used to assess 
pain [30, 31]. In cases where only WOMAC was available 
a threshold of 3 was used on the WOMAC pain subscale, 
this threshold was determined by the previous expert con-
sensus and external validity study [22]. Radiographic OA 
was defined using the Kellgren and Lawrence (K/L) scor-
ing method, grade 2, or above, and alternatively, an equiva-
lent combination of radiographic features (osteophytes and 
joint space narrowing) from other validated scoring methods 
(such as the OARSI atlas) [32, 33].
Subjects were divided into four categories: (1) no knee 
pain or radiographic OA (Pain-/ROA-); (2) radiographic OA 
with no pain (ROA); (3) knee pain with no radiographic OA 
(POA); (4) pain and radiographic OA (PROA). Person-level 
OA was calculated by assessing the OA status for each joint 
and using the ‘highest’ level of OA based on this system. For 
example, if a subject had no knee pain or radiographic OA 
(cat 1) in their right knee and radiographic OA with no pain 
(cat 2) in their left knee, their person-level knee OA status 
would be radiographic OA with no pain (cat 2).
Primary outcome: time‑to‑mortality
Each cohort contained a status variable (dead/alive) and 
a time-to-censoring variable for each participant. Three 
cohorts (Chingford, Johnston County, TasOAC) determined 
the date of death using nationally linked records, while the 
remaining cohorts used other methods to determine the 
date of death such as updates from Primary Care systems, 
death registries or municipal administration, family, medical 
records, and periodic examinations or contacts.
In cohorts where subjects were lost to follow-up at an 
unknown date, the previous visit when subjects had data 
was used as the last date where mortality status was known. 
Time-to-status was calculated from the baseline visit, deter-
mined by when knee X-rays and pain were assessed, to the 
last date that the subject’s status was known. Survival was 
calculated using person-years attributing to the analysis.
Potential confounders
The potential confounders accounted for in this analysis 
were: age; sex; race; BMI; smoking; drinking; cardiovas-
cular disease (CVD); and diabetes. These were based on 
clinical applicability and consistent availability across each 
cohort. To be modelled consistently between cohorts, vari-
ables were categorised into the broadest level of informa-
tion available in any single cohort. For example, one cohort 
contained detailed data on the lifetime use of all tobacco 
products enabling the generation of a ‘dose’, while another 
cohort simply asked whether they were current, former, or 
never smokers. This second option was then generated for 
each cohort. Pain medication, such as NSAIDs, was not con-
sidered a potential confounder in this analysis, as it is on the 
causal pathway between painful OA and mortality, and a 
mediation analysis on this scale would not have been feasible 
due to both limitations in the data and in the methodology.
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Age was defined as age at the time of baseline clinic visit 
when OA variables were assessed. Race was included as a 
potential confounder for any cohort which had more than one 
race category. Chingford, TasOAC, and Framingham have 
predominantly Caucasian participants; Johnston County and 
MOST have both Caucasian and African American subjects; 
and Wuchuan has predominantly Chinese subjects. BMI was 
calculated for each cohort using height and weight variables 
(weight/height in metres [2]). Extreme values were identified 
in several cohorts; however, due to the wide variety of sub-
jects found in our dataset, we only excluded impossible (i.e. 
outside any known values) rather than improbable values. 
Smoking, Alcohol, Diabetes, and CVD were all generated 
as binary variables. Smoking was calculated with current/
former smokers and never smokers. Alcohol was grouped by 
more than one drink per week versus none or one drink per 
week. Diabetes was based on the presence of self-reported 
clinically diagnosed diabetes, and CVD was calculated using 
self-reported responses to previous ischaemic heart disease, 
and general heart problems.
Statistical methods: descriptive statistics
Descriptive statistics [percentages, means (standard devia-
tions), and medians (inter-quartile ranges)] were calculated 
for baseline characteristics of all cohorts using all available 
data. The difference between baseline characteristics in sub-
jects with and without complete data (OA and confounders) 
was calculated using t tests (or Wilcoxon–Mann–Whitney) 
for continuous variables and Chi-square tests (or Fisher’s 
exact) for binary and categorical variables. Descriptive sta-
tistics for baseline characteristics and time-to-mortality data 
were stratified by the categories, no pain/no ROA, POA, 
ROA and PROA.
Statistical methods: missing data
There were three potential types of missing data to consider 
within our analyses. To identify data that was missing at 
random (MAR) and missing completely at random (MCAR), 
we tested patterns and predictors of missingness for all expo-
sures and potential confounders. We identified several MAR 
variables and ensured to include any required predictors in 
the imputation model. All other variables were assumed to 
be MCAR, a non-testable assumption. There were also sys-
tematically missing variables, which were missing in their 
entirety in a single cohort. Appendix 2 shows the systemati-
cally missing and MAR/MCAR variables for each cohort.
Multiple imputation with chained equations (MICE) 
was used to impute any missing data for both the primary 
risk factor and for confounders [34, 35]. Systematically 
missing variables (i.e., variables which were missing in 
their entirety) were excluded from all models and analyses. 
Participants with missing mortality data were excluded 
from all analysis (cohorts had no more than three percent 
missing mortality data). The Nelsen–Aalen estimator was 
used to approximate the baseline hazards in the imputa-
tion models [36]. Variables used for the imputation models 
were congruent with the analysis model described in the 
next section. Missing PROA and race were modelled using 
multinomial logistic regression; BMI by linear regression; 
sex, smoking, alcohol, CVD, and diabetes by logistic 
regression. Age was modelled by predictive mean match-
ing due to non-normality from being restricted between 
ages 45 and 80 [37].
Statistical methods: survival analysis
Cox proportional hazard regression models were used to 
estimate hazard ratios (HRs) and 95% confidence intervals 
(95% CIs) between three OA categories (POA, ROA, PROA) 
and the time-to all-cause-mortality using no pain/no ROA as 
the comparator group for each analysis. Three models were 
run: (1) univariable models assessed OA alone; (2) adjusted 
for age, sex and race; (3) adjusted for age, sex, race, BMI, 
smoking, alcohol, CVD, and diabetes. Models run in the 
Johnston County cohort also included a variable for recruit-
ment wave. Several cohorts were systematically missing 
key potential confounders (primarily smoking and alcohol) 
(Appendix 2).
To satisfy the assumptions of the Cox proportional hazard 
model linearity was assessed between continuous variables 
(age and BMI) and time to death using fractional polynomi-
als and kernel. The proportional hazard assumption of the 
primary risk factor (OA) was tested using Schoenfeld residu-
als. Due to the violation of this proportionality assumption, 
Johnston County was truncated to the 13-year follow-up post 
hoc, which was the maximum follow-up time of one of the 
recruitment waves. This corrected the violation of propor-
tionality for the PROA variable, although reduced the power 
of this cohort. A priori interactions of OA and age, and OA 
and BMI were tested in all cohorts.
Statistical methods: individual participant data 
analysis
Individual participant-level meta-analysis methods were 
utilised, using a two-staged approach [21, 38]. In the first 
stage, hazard ratios (HR) and 95% confidence intervals (CI) 
were first produced for each individual cohort. Data were 
pooled in the second stage using random-effects analysis, 
using the Hartung–Knapp estimation to account for uncer-
tainty around the tau statistic [39, 40].
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The Stata admetan command was used to produce the 
pooled estimates in addition to forest plots which graphically 
demonstrate the results [41]. All analyses were conducted 
using Stata version 13·0 statistical software (StataCorp, Col-
lege Station, Texas, USA).
Role of funding source
Versus Arthritis UK (formally Arthritis Research) had no 
role in study design, data collection, data analysis, data inter-
pretation, or writing of the report. Members of the PCCOA 
steering committee from Osteoarthritis Research Society 
International (a non-profit scientific organisation) had roles 
in study development and interpretation as outlined in the 
author contribution section with all contributors named in 
the writing group. The corresponding author had full access 
to all the data in the study and had final responsibility for the 
decision to submit for publication (Fig. 1).
Results
10,723 participants in six cohorts from four countries were 
included in the analyses. All cohorts had less than 3% miss-
ing mortality data and less than 12% missing risk factor or 
confounder data. Participants with missing mortality data 
were excluded, whilst those missing risk and confounder 
data were included in imputed analyses. In several cohorts, 
there was a statistically significant difference in OA, age, 
BMI, diabetes, and CVD in subjects with and without miss-
ing data (Appendix 3).
Table 1 shows the baseline demographics for all cohorts 
stratified by baseline OA. Median follow-up for this analy-
sis ranged from 5·6 to 20·0 years after baseline. There was 
substantial variability in the baseline age (54.3–62.7 years), 
BMI (22.5–30.7 kg/m2), prevalence of PROA (6.7–33.3%), 
and the duration of follow-up in each cohort, such that the 
percentage of subjects that died in each cohort ranged from 
2.9 to 22.3% (Table 2).
The univariable meta-analysis (Fig. 2) shows a non-
significant pooled hazard ratio (HR and 95% confidence 
Fig. 1  a–c Forest plots of univariable models: a ROA; b POA; c PROA compared to Pain-/ROA-
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interval) of 1.41 (0.98, 2.01) for ROA. Both POA and PROA 
were significantly associated with reduced time-to-mortality 
(1.42 [1.13, 1.79], and 1.94 [1.58, 2.39], respectively) when 
compared with participants with no pain or ROA. In the 
model adjusted for age, sex, and race only, the effect size 
was attenuated and remained non-significant for ROA (1.0 
[0.70, 1.44]); increased slightly and remained significant for 
POA (1·44 [1.11, 1.85]); and was attenuated for PROA (1.36 
[1.18, 1.56]) compared with the univariable models.
In the fully adjusted model (age, sex, race, BMI, smoking, 
alcohol consumption, CVD, and diabetes), ROA remained 
non-significant, and participants with POA or PROA had 
a 35% (HR 1·35 [1.13, 1.63]) and 37% (HR 1·37 [1.22, 




This individual participant-level meta-analysis of over 
100,000 people from four countries revealed that partici-
pants with knee pain only, or a combination of knee pain and 
radiographic OA, had an increased association with reduced 
time-to-mortality, independent of age, sex, and race (HRs 
of 1.36–1.44). To explore whether the association could be 
explained by co-morbid conditions, the models were further 
adjusted for BMI, smoking, alcohol, CVD, and diabetes. The 
results remained consistent with HRs of 1.35 for those with 
POA and 1.37 for those with PROA, compared to partici-
pants without knee pain and ROA (pain-/ROA-). Interest-
ingly, we did not observe an association with time-to-mortal-
ity in participants with radiographic changes alone (ROA), 
suggesting that it is pain or some functional consequence of 
pain such as walking disability or reduced physical activity, 
rather than the structural aspect of knee OA, that may be 
driving the increased association with premature mortal-
ity [42, 43]. While many studies have found an association 
between OA-related pain and premature mortality, the poten-
tial pathways that explain this association is still unclear. A 
study using large population-based data sets to investigate 
the effect of pain phenotype on the association between pain 
and mortality found that the impact of pain in daily life was 
more important than the presence or extent of pain in the 
relationship between pain and mortality [44]. Findings from 
one of the same cohorts examining the potential mechanisms 
between OA and all-cause mortality highlighted frequent 
walking as a potential target to reduce all-cause mortality. 
While anxiety, depression, and unrefreshed sleep had statis-
tically significant effects, the extent of their mediation effect 
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Results in the context of other studies
Three recent meta-analyses found no association between 
OA and mortality, with pooled effect sizes of 0.91 (0.68, 
1.23), 1.06 (0.88, 1.28), and 1.21 (0.82, 1.78) in a knee only 
analysis [7–9]. All three articles combined results of studies 
which used multiple forms of OA diagnosis, including clini-
cian diagnosed OA, self-reported clinical diagnosis, pain, 
and radiographic OA, increasing the measurement error 
of the OA variable. Two of the meta-analyses combined 
studies with knee, hip, and hand data into a single effect 
size [7, 9]. Individual studies, which assessed knee pain 
and radiographic OA with mortality, tend to report higher 
effect sizes more consistent without our results. For instance, 
Liu et al. [15] reported a borderline significant HR of 1.90 
(1.00, 3.50), while Tsuboi et al. [12] reported a significant 
HR of 2.32 (1.41, 3.80), as did Kluzek et al. [14], HR of 
1·47 (1.08, 2.01). Cleveland et al. observed an increased 
risk of all-cause mortality in participants with knee pain 
alone (HR of 1.19 [1.04–1.35]) and those with symptomatic 
knee OA (HR of 1.17 [1.03–1.34]) [46]. Castano Betancourt 
et al. and Neusch et al. combined hip and knee pain/ROA, 
and both found a significant association with premature 
mortality (1.23 and 1.55, respectively) [11, 47], supporting 
the concept that the association of knee OA with reduced 
time-to-mortality may be driven by pain rather than by struc-
tural changes identified by radiographs. In this analysis, we 
treated a number of comorbidities as potential confound-
ers; however, the relationship between these comorbidities 
and OA is poorly understood and may ultimately be part 
of the causal pathway; therefore, the associations we found 
here may not represent a causal association between OA and 
mortality. We could be underestimating this association if 
some of the potential confounders are actually mediators 
on the causal pathway, and we may be overestimating the 
Table 2  Mortality information 
by baseline knee osteoarthritis 
status
Mortality information Osteoarthritis
None ROA POA PROA
Chingford
 Total N 588 75 232 64
 No of deaths 67 19 42 17
 Median follow-up 20.0 (20.0, 20.0) 20.0 (19.4, 20.0) 20.0 (20.0, 20.0) 20.0 (18.6, 20.0)
 Median time-to-death 14.2 (8.4, 17.1) 13.5 (8.0, 16.2) 14.1 (10.6, 17.9) 12.1 (6.7, 16.2)
Johnston County
 Total N 1707 378 1023 654
 No of deaths 300 96 250 208
 Median follow-up 12.5 (9.4, 13.0) 12.0 (7.5, 13.0) 11.5 (9.3, 13.0) 10.8 (8.3, 13.0)
 Median time-to-death 7.3 (4.2, 10.6) 7.4 (4.3, 10.6) 7.1 (4.3, 9.9) 6.7 (3.7, 9.8)
Framingham
 Total N 594 63 181 48
 No of deaths 44 6 17 1
 Median follow-up 11.8 (10.8, 12.5) 12.3 (11.53, 12.7) 11.6 (10.8, 12.5) 12.2 (11.8, 12.7)
 Median time-to-death 8.3 (4.9, 10.7) 6.0 (3.7, 8.3) 9.0 (7.2, 10.6) 13.2 (13.2, 13.2)
MOST
 Total N 827 503 608 968
 No of deaths 14 10 26 34
 Median follow-up 5.6 (5.5. 5.8) 5.6 (5.5. 5.8) 5.6 (5.5. 5.8) 5.6 (5.5. 5.8)
 Median time-to-death 2.7 (1.9, 4.8) 4.8 (4.2, 5.3) 4.0 (2.7, 4.9) 3.2 (1.8, 5.0)
TasOAC
 Total N 206 372 83 219
 No of deaths 31 53 10 39
 Median follow-up 12.0 (8.8, 13.1) 11.9 (8.2, 12.9) 11.6 (9.7, 13.0) 10.4 (5.0, 12.6)
 Median time-to-death 9.1 (6.4, 10.9) 7.9 (6.1, 10.5) 9.8 (6.4, 10.8) 6.4 (3.7, 9.5)
Wuchuan
 Total N 469 42 698 107
 No of deaths 36 4 37 19
 Median follow-up 8.3 (8.3, 8.3) 8.3 (8.3, 8.3) 8.3 (8.3, 8.3) 8.3 (8.3, 8.3)
  Median time-to-death 5.9 (4.0, 7.5) 5.4 (3.3, 6.4) 5.7 (3.8, 6.8) 4.8 (3.9, 5.9)
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association depending on how well our adjusted models are 
accounting for confounding.
Patients with OA have on average 2·6 moderate-to-
severe co-morbidities [48] and 31% of patients have five 
or more other chronic conditions [49]. Our fully adjusted 
models, which included lifestyle factors and cardiovascu-
lar conditions, did not change substantially from the mod-
els adjusted for age, sex, and race. This may indicate that 
the additional potential confounders we have adjusted for 
do not have a substantial confounding effect on the asso-
ciation between OA and reduced time-to-mortality. This 
suggests that either the association is driven by OA or is 
due to residual confounding caused by measurement error 
in self-reported variables and/or by the lack of potential 
confounders such as physical activity and occupation. An 
additional potential source of unmeasured confounding 
is the pain sensitization, which may effect the relation of 
painful knee OA and mortality, and should be pursued in 
future research. The current study focuses on the knee; 
however, it is known that limitations in activities of daily 
living and mobility vary according to hip or knee site 
[50]; previous studies have also found an increased risk 
of mortality in individuals with hip symptoms [51].
Strengths and limitations
A limitation of this study is that the included cohorts were 
designed as independent studies and were not originally 
Fig. 2  a–c Forest plots of fully adjusted models: a ROA; b POA; c PROA compared to Pain-/ROA-
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designed to be directly compared to one another. Therefore, 
osteoarthritis was assessed differently between cohorts. It is 
known that even small variations in the way a pain question 
is worded, or X-rays are graded, can result in differences 
in OA prevalence [22, 52]. To minimise this variation, we 
made every effort to harmonise pain and ROA variables 
between cohorts by conducting an international expert con-
sensus study [22].
One of the strengths of our study, unlike traditional meta-
analyses, is that we actively sought cohorts that had not 
previously published on the association between OA and 
mortality, to avoid publication bias. To also capture people 
without the symptomatic aspects of OA, we restricted our 
studies to those that included the general population and 
one enhanced risk factor cohort. These people would not 
be included in clinical OA cohorts, which is a known issue 
in the accurate reporting of the true burden of OA [53, 54].
The MOST cohort included additional focussed recruit-
ment to include a larger proportion of participants that were 
older, female, overweight, or had knee surgery/injury, all 
factors associated with an increased risk of OA. Therefore, 
the reference group (without pain or ROA) is likely to have 
a higher prevalence of OA risk factors than the pain and 
ROA-free group in other cohorts, which may have biased 
our results toward the null in this cohort.
The follow-up of the included studies ranged from 5.6 to 
20.0 years; however, only baseline knee OA and confound-
ers were included in the analysis, meaning that participants 
may have changed OA categories after the baseline visit, 
resulting in possible misclassification bias. A further poten-
tial limitation is that the age of our participants at baseline 
ranged between 45 and 80; however, the mean age between 
cohorts was relatively similar with lowest having a mean age 
of 56.0 and the highest with a mean age of 64.4 (Table 1).
Both a strength and limitation of the current study is that 
we included cohorts from different countries, with different 
races, cultures and health care systems. Confounders were 
harmonised using the least detailed information available 
in any single cohort at the baseline visit only, which likely 
increased our risk of residual confounding in our models. 
However, by harmonising the individual confounders and 
adjusting for them consistently between studies, we have 
reduced unnecessary heterogeneity between studies. There-
fore, remaining differences between cohorts are more likely 
to reflect racial, country, and/or cultural variations rather 
than how variables were defined, or which statistical models 
were used.
Previous individual cohort or meta-analysis studies have 
suggested that a large proportion of the increased risk of mor-
tality is due to cardiovascular mortality [9, 14]. Cause-specific 
mortality was not available in the majority of our cohorts and 
justifies further investigation. Likewise, medical detail was 
not available across all cohorts to consider the effect of pain-
relieving medications. Pain medication is on the casual path-
way between painful OA and mortality, and by not including it 
in our model, our associations are ultimately combining both 
the direct effect of OA on mortality and the indirect effect of 
OA through pain medication on mortality. Future research 
using mediation analysis will help to clarify this pathway.
IPD meta-analyses are time-consuming and resource 
intensive compared with traditional meta-analyses; however, 
they allow for standardising exposures, outcomes, and statis-
tical methods, and, more importantly, avoid publication bias 
by not being limited to the inclusion of previously published 
studies, which is rarely done in the traditional meta-analysis.
Conclusion
This study is the first individual participant-level data meta-
analysis of knee osteoarthritis and premature mortality. It dem-
onstrates that participants with knee pain only or a combina-
tion of knee pain and radiographic OA had a 35–37% increased 
association with reduced time-to all-cause-mortality independ-
ent of age, sex, race, BMI, smoking, alcohol, CVD, or diabetes. 
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With the increasing prevalence of knee OA, it is essential that 
clinicians and public health bodies are aware of the potential 
that people with OA may have an increased burden of prema-
ture mortality compared to people without OA. This finding 
highlights that osteoarthritis is a serious disease and supports 
the need for further research to identify whether OA-related 
mechanisms are causally associated with premature mortality.
Appendix 1: Cohort inclusion flow chart




































18 cohorts excluded based on being non-observational or 
non-community based or a case- control study 
13 cohorts excluded based on missing or non-targeted 
information for knee pain/radiographic OA data 
2 cohorts excluded based on lack of mortality or detailed 
mortality (time to death)  
40 cohorts identified using search terms “knee 
osteoarthritis” and “cohort” AND non-traditional 
methods (conferences, OA research networks) 
22 cohorts screened for knee pain/radiographic data 
9 Cohorts screened for mortality data 
7 Cohorts identified for IPD analysis 
6 cohorts for which IPD sought  
Cohorts for which IPD were provided  
(N=6) 
N= 11,522 participants for whom data 
were provided 
N= 291 participants for whom data 
weren’t provided  
Cohorts included in analysis  
(n=6) 
N= 10,723 participants included in 
analysis  
N= 799 participants excluded (due to 
presence of Rheumatoid Arthritis, 
aged Age under 45 or over 80 years 
old or missing mortality data) 
Cohorts for which aggregate data 
were provided 
 (N=0) 
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996 .. 1154 2938 983 ..
  Age (45–
80 years)
992 3968 905 2938 980 1017
  Mortality 
data











  PROA 959 3762 905 2906 880 1016
  Sex 992 3762 886 2906 880 1016
  Race 992 3762 886 2906 .. 1016
  BMI 959 3756 886 2905 880 1016
  Alcohol 959 .. 884 .. 880 ..
  Smoking 959 3681 883 2905 879 ..
  CVD 956 3681 869 2824 843 1016





956 3676 865 2762 843 1016
a Total N after imputation
Appendix 3: Complete case vs subjects 
with missing values for each cohort
See Tables 3, 4, 5, 6, 7, 8.     
Table 3  Johnston County complete case vs subjects with any missing 
values for risk factor and confounders
t tests (or Wilcoxon–Mann–Whitney test) for continuous variables 
and  Chi2-tests (or Fishers exact) for categorical variable
Baseline variable Complete case Missing values p value
N = 3918 3762 156
Osteoarthritis
 None 1707 (45.4%) 0
 ROA 378 (10.1%) 0
 POA 1023 (27.2%) 0
 PROA 654 (17.4%) 0
Age 59.8 (9.4) 63.3 (10.4) 0.000
Sex (% female) 2348 (62.4%) 109 (69.9%) 0.059
Race
 Caucasian 2466 (65.6%) 102 (65.4%) 0.966
 African American 1296 (34.5%) 54 (34.6%)
BMI (continuous) 29.7 (6.4) 29.3 (6.1) 0.4253
Ex/current smoking 
(binary)
1885 (51.1%) 48 (44.0%) 0.145
CVD2 (heart/stroke) 1057 (28.1%) 41 (26.3%) 0.621
Diabetes 487 (13.0%) 22 (14.5%) 0.588
Table 4  Framingham complete case vs subjects with any missing val-
ues for risk factor and confounders
t tests (or Wilcoxon–Mann–Whitney test) for continuous variables 
and  Chi2 tests (or Fishers exact) for categorical variables
Baseline variable Complete case Missing values p value
N = 905 886 19
Osteoarthritis
 None 594 (67.0%) 0
 ROA 63 (7.1%) 0
 POA 181 (20.4%) 0
 PROA 48 (5.4%) 0
Age 56.0 (7.6) 57.2 (7.6) 0.466
Sex (% female) 461 (52.0%) 13 (68.4%) 0.157
Race
 Caucasian 886 (100%) 19 (100%)
BMI (continuous) 27.3 (4.6) 26.8 (3.1) 0.809
Ex/current Smoking 
(binary)
568 (64.2%) 12 (63.2%) 0.927
CVD2 (heart/stroke) 30 (3.4%) 0
Diabetes 39 (4.4%) 1 (5.3%) 0.860
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Table 5  Chingford complete case vs subjects with any missing values for risk factor and confounders
t tests (or Wilcoxon–Mann–Whitney test) for continuous variables and  Chi2-tests (or Fishers exact) for categorical variables
Baseline variable Complete case Missing values p value
N = 857 683 174
Osteoarthritis
 None 483 (70.7%) 0
 ROA 129 (18.9%) 0
 POA 41 (6.0%) 0
 PROA 30 (4.4%) 0
Age 57.9 (6.0) 58.1 (5.9) 0.697
BMI (continuous) 26.3 (4.4) 26.4 (4.3) 0.735
Ex/current smoking (binary) 317 (46.4%) 70 (40.2) 0.143
CVD2 (heart/stroke) 25 (4.3%) 10 (7.4%) 0.134
Diabetes 6 (0.9%) 3 (1.7%) 0.329
Table 6  MOST complete case vs subjects with any missing values for risk factor and confounders
t tests (or Wilcoxon–Mann–Whitney test) for continuous variables and  Chi2-tests (or Fishers exact) for categorical variables
Baseline variable Complete case Missing values p value
N = 2936 2906 30
Osteoarthritis
 None 827 (28.5%) 0
 ROA 503 (17.3%) 0
 POA 608 (20.9%) 0
 PROA 968 (33.3%) 0
Age 62.5 (8.1) 64.3 (6.9) 0.215
Sex (% female) 1759 (60.5%) 16 (53.3%) 0.423
Race
 Caucasian 2449 (84.3%) 21 (70.0%) 0.058
 African American 418 (14.4%) 8 (26.7%)
 Other 39 (1.3%) 1 (3.3%)
BMI (continuous) 30.7 (5.9) 30.4 (6.7) 0.805
Ex/current Smoking (binary) 1292 (44.5%) 13 (43.3%) 0.902
CVD2 (heart/stroke) 335 (11.9%) 4 (13.8%) 0.749
Diabetes 304 (10.7%) 3 (10.0%) 0.901
542 Aging Clinical and Experimental Research (2021) 33:529–545
1 3
Acknowledgements This study was funded by the Sport, Exercise 
and Osteoarthritis Centre: Versus Arthritis and the PCCOA, Osteo-
arthritis Research Society International. This study would not have 
been possible without the late Professor Doug Altman, who was instru-
mental in the study conception, design, and analysis. We are grateful 
to Sally Sheard for her help in acquiring and harmonising the data 
used in this manuscript. PCCOA (Pre-Competitive Consortium for 
Osteoarthritis) OARSI steering committee: Lyn March (lyn.march@
sydney.edu.au); Gillian Hawker (g.hawker@utoronto.ca); Philip Cona-
ghan (P.Conaghan@leeds.ac.uk); Virginia Byers Kraus (kraus004@
duke.edu); Ali Guermazi (guermazi@bu.edu); David Hunter (David.
Hunter@sydney.edu.au); Jeffrey N. Katz (jnkatz@bwh.harvard.edu); 
Tim McAlindon (tmcalindon@tuftsmedicalcenter.org); Tuhina Neogi 
(tneogi@bu.edu); Lee Simon (lssconsult@aol.com); Marita Cross 
(marita.cross@sydney.edu.au); Lauren King (laurenkarinaking@
gmail.com).
Author contributions KML, LSG, NKA, CC, GJ, JMJ, MN, and 
PCCOA were involved in the study conception. KML, LSG, DA, NKA, 
GC, CC, AJ, MN, JN, and NY contributed to study design. NKA, DF, 
JG, JMJ, JL, LFC, RC, MEB, QL, and MN contributed data. KML, 
LSG, and MTSS analysed the data. KML, LSG, DA, NKA, GC, CC, 
DH, AJ, MN, and MTSS interpreted the data. LSG and KML undertook 
the literature search and drafted the manuscript. All authors critically 
reviewed the manuscript. KML, LSG, NKA, GC, CC, DF, DH, GJ, 
JMJ, LFC, RC, MEB, AJ, JL, QL, MN, JN, MTSS, NY, and PCCOA 
approved the final version. KML had full access to all data in the study 
and had final responsibility for the decision to submit for publication.
Funding This study was funded by the Centre for Sport Exercise and 
Osteoarthritis Research Versus Arthritis (grant 21595).
Compliance with ethical standards 
Conflict of interest Dr Leyland reports grants from the Centre for Sport, 
Exercise and Osteoarthritis Research Versus Arthritis, during the con-
duct of the study. Dr Gates is funded by the Centre for Sport, Exercise 
and Osteoarthritis Research Versus Arthritis. Professor Arden reports 
grants from the Centre for Sport, Exercise and Osteoarthritis Research 
Versus Arthritis, grants from Merck, and personal fees from Merck, Pfiz-
er/Lilly. Professor Cooper reports personal fees from Alliance for Better 
Bone Health, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfiz-
er, Roche, Servier, Takeda, and UCB. Professor Hunter reports personal 
fees from Merck Serono, Pfizer, Lilly, and TLCBio. Professor Jordan re-
ports grants from National Institutes of Health, Centers for Disease Con-
trol and Prevention, American College of Rheumatology, personal fees 
from Samumed, Flexion, Osteoarthritis Research Society International, 
and National Institutes of Health. Professor Judge reports personal fees 
from Anthera Pharmaceuticals Ltd, Freshfields, Bruckhaus, and Derrin-
ger. Professor Jones reports personal fees from BMS, Roche, Abbvie, 
Table 7  TaSOAC complete case 
vs subjects with any missing 
values for risk factor and 
confounders
t tests (or Wilcoxon–Mann–Whitney test) for continuous variables and  Chi2-tests (or Fishers exact) for cat-
egorical variables
Baseline variable Complete case Missing values p value
N = 445 410 35
Osteoarthritis (no-side specific pain)
 None 96 (23.4%) 0
 ROA 157 (38.3%) 0
 POA 42 (10.2%) 0
 PROA 115 (28.1%) 0
Age 64.4 (7.9) 65.1 (8.7) 0.6464
Sex (% female) 209 (51.0%) 18 (51.4%) 0.959
Race
Caucasian white 263 (98.1%) 19 (100%) 0.835
Asian 2 (0.8%)
Indigenous Australian 3 (1.1%)
BMI (continuous) 28.2 (5.2) 27.6 (4.0) 0.4707
Ex/current Smoking (binary) 224 (54.6%) 20 (58.8%) 0.637
CVD2 (heart/stroke) 44 (11.7%) 5 (17.2%) 0.378
Diabetes 36 (9.6%) 4 (13.8%) 0.463
Table 8  Wuchuan complete case vs subjects with any missing values 
for risk factor and confounders
Data is not presented for missing values, and no tests were done com-
paring groups due to small number of participants with missing data
Baseline variable Complete case Missing values p value







Sex (% female) 515 (50.7%)
BMI [mean (SD)] 22.5 (3.3)
CVD (heart/stroke) (%) 119 (11.7%)
Diabetes 5 (0.5%)
543Aging Clinical and Experimental Research (2021) 33:529–545 
1 3
Amgen, Lilly, Novartis, Jannsen, and grants from Covance. Professor 
Felson has nothing to disclose.
Statement of human and animal rights All procedures performed in 
each original cohort study were in accordance with the ethical stand-
ards of the institution and the associated national research committee.
Informed consent All participants provided written informed consent 
to participate in each original cohort study.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
References
 1. James SL, Abate D, Abate KH et al (2018) Global, regional, and 
national incidence, prevalence, and years lived with disability 
for 354 diseases and injuries for 195 countries and territories, 
1990–2017: a systematic analysis for the Global Burden of Dis-
ease Study 2017. Lancet 392:1789–1858
 2. Murphy L, Schwartz TA, Helmick CG et al (2008) Lifetime risk of 
symptomatic knee osteoarthritis. Arthritis Rheum 59:1207–1213
 3. Losina E, Walensky RP, Reichmann WM et al (2011) Impact of 
obesity and knee osteoarthritis on morbidity and mortality in older 
Americans. Ann Intern Med 154:217–226
 4. Litwic A, Edwards MH, Dennison EM et al (2013) Epidemiology 
and burden of osteoarthritis. Br Med Bull 105:185–199
 5. Steultjens MP, Dekker J, van Baar ME et al (2000) Range of joint 
motion and disability in patients with osteoarthritis of the knee or 
hip. Rheumatology (Oxford) 39:955–961
 6. Hochberg MC (2008) Mortality in osteoarthritis. Clin Exp Rheu-
matol 26(Suppl 51):S120–S124
 7. Xing D, Xu Y, Liu Q et al (2016) Osteoarthritis and all-cause 
mortality in worldwide populations: grading the evidence from a 
meta-analysis. Sci Rep 6:24393
 8. Veronese N, Cereda E, Maggi S et al (2016) Osteoarthritis and 
mortality: a prospective cohort study and systematic review with 
meta-analysis. Semin Arthritis Rheum 46:160–167
 9. Han X, Liu Z, Kong L et al (2017) Association between osteoar-
thritis and mortality: a meta-analysis. Int J Clin Exp Med 10:1094
 10. Holbrook TL, Wingard DL, Barrett-Connor E (1990) Self-
reported arthritis among men and women in an adult community. 
J Community Health 15:195–208
 11. Nuesch E, Dieppe P, Reichenbach S et al (2011) All cause and dis-
ease specific mortality in patients with knee or hip osteoarthritis: 
population based cohort study. BMJ 342:d1165
 12. Tsuboi M, Hasegawa Y, Matsuyama Y et al (2011) Do musculo-
skeletal degenerative diseases affect mortality and cause of death 
after 10 years in Japan? J Bone Miner Metab 29:217–223
 13. Cacciatore F, Della-Morte D, Basile C et al (2014) Long-term 
mortality in frail elderly subjects with osteoarthritis. Rheumatol-
ogy (Oxford) 53:293–299
 14. Kluzek S, Sanchez-Santos MT, Leyland KM et al (2016) Painful 
knee but not hand osteoarthritis is an independent predictor of 
mortality over 23 years follow-up of a population-based cohort 
of middle-aged women. Ann Rheum Dis 75:1749–1756
 15. Liu Q, Niu J, Huang J et al (2015) Knee osteoarthritis and all-
cause mortality: the Wuchuan Osteoarthritis Study. Osteoarthritis 
Cartil 23:1154–1157
 16. Turkiewicz A, Neogi T, Bjork J et al (2016) All-cause mortality in 
knee and hip osteoarthritis and rheumatoid arthritis. Epidemiol-
ogy 27:479–485
 17. Sterne JAC, Egger M, Smith GD (2001) Investigating and deal-
ing with publication and other biases in meta-analysis. BMJ 
323:101–105
 18. Altman DG (2001) Systematic reviews of evaluations of prognos-
tic variables. BMJ 323:224–228
 19. Riley RD, Simmonds MC, Look MP (2007) Evidence synthesis 
combining individual patient data and aggregate data: a systematic 
review identified current practice and possible methods. J Clin 
Epidemiol 60:431–439
 20. Altman DG, Trivella M, Pezzella F et al (2007) Systematic review 
of multiple studies of prognosis: the feasibility of obtaining indi-
vidual patient data. In: Auget J-L, Balakrishnan N, Mesbah M, 
Molenberghs G (eds) Advances in statistical methods for the 
health sciences: applications to cancer and AIDS studies, genome 
sequence analysis, and survival analysis. Birkhäuser, Boston, pp 
3–18
 21. Riley RD, Lambert PC, Abo-Zaid G (2010) Meta-analysis of indi-
vidual participant data: rationale, conduct, and reporting. BMJ 
340:c221
 22. Leyland KM, Gates LS, Nevitt M et al (2018) Harmonising meas-
ures of knee and hip osteoarthritis in population-based cohort 
studies: an international study. Osteoarthritis Cartil 26:872–879
 23. Burke DL, Ensor J, Riley RD (2017) Meta-analysis using indi-
vidual participant data: one-stage and two-stage approaches, and 
why they may differ. Stat Med 36:855–875
 24. Jordan JM, Linder GF, Renner JB et al (1995) The impact of 
arthritis in rural populations. Arthritis Care Res 8:242–250
 25. Feinleib M, Kannel WB, Garrison RJ et al (1975) The Framing-
ham offspring study. Design and preliminary data. Prev Med 
4:518–525
 26. Felson DT, Naimark A, Anderson J et al (1987) The prevalence 
of knee osteoarthritis in the elderly the Framingham osteoar-
thritis study. Arthritis Rheum 30:914–918
 27. Hart DJ, Mootoosamy I, Doyle DV et al (1994) The relationship 
between osteoarthritis and osteoporosis in the general popula-
tion: the Chingford Study. Ann Rheum Dis 53:158–162
 28. Kang X, Fransen M, Zhang Y et al (2009) The high preva-
lence of knee osteoarthritis in a rural Chinese population: the 
Wuchuan osteoarthritis study. Arthritis Rheum 61:641–647
 29. Ding C, Parameswaran V, Cicuttini F et al (2008) Associa-
tion between leptin, body composition, sex and knee cartilage 
morphology in older adults: the Tasmanian older adult cohort 
(TASOAC) study. Ann Rheum Dis 67:1256–1261
 30. Anderson JJ, Felson DT (1988) Factors associated with osteo-
arthritis of the knee in the first national Health and Nutrition 
Examination Survey (HANES I). Evidence for an association 
with overweight, race, and physical demands of work. Am J 
Epidemiol 128:179–189
 31. Bellamy N, Buchanan WW, Goldsmith CH et al (1988) Valida-
tion study of WOMAC: a health status instrument for measuring 
clinically important patient relevant outcomes to antirheumatic 
drug therapy in patients with osteoarthritis of the hip or knee. J 
Rheumatol 15:1833–1840
 32. Kellgren JH, Lawrence JS (1957) Radiological assessment of 
osteo-arthrosis. Ann Rheum Dis 16:494–502
544 Aging Clinical and Experimental Research (2021) 33:529–545
1 3
 33. Altman RD, Gold GE (2007) Atlas of individual radio-
graphic features in osteoarthritis, revised. Osteoarthritis Cartil 
15:A1–A56
 34. Royston P (2007) Multiple imputation of missing values: further 
update of ice, with an emphasis on interval censoring. Stata J 
7:445–464
 35. van Buuren S (2007) Multiple imputation of discrete and continu-
ous data by fully conditional specification. Stat Methods Med Res 
16:219–242
 36. White IR, Royston P (2009) Imputing missing covariate values 
for the Cox model. Stat Med 28:1982–1998
 37. Vink G, Frank LE, Pannekoek J et al (2014) Predictive mean 
matching imputation of semicontinuous variables. Stat Neerl 
68:61–90
 38. Thomas D, Radji S, Benedetti A (2014) Systematic review of 
methods for individual patient data meta-analysis with binary 
outcomes. BMC Med Res Methodol 14:79
 39. Hartung J, Knapp G (2001) A refined method for the meta-anal-
ysis of controlled clinical trials with binary outcome. Stat Med 
20:3875–3889
 40. IntHout J, Ioannidis JPA, Borm GF (2014) The Hartung–Knapp–
Sidik–Jonkman method for random effects meta-analysis is 
straightforward and considerably outperforms the standard Der-
Simonian–Laird method. BMC Med Res Methodol 14:25
 41. Harris R, Bradburn M, Deeks J et al (2008) metan: fixed- and 
random-effects meta-analysis. Stata J 8:3–28
 42. Hawker GA, Croxford R, Bierman AS et al (2014) All-cause mor-
tality and serious cardiovascular events in people with hip and 
knee osteoarthritis: a population based cohort study. PloS one 
9:e91286-e
 43. Liu Q, Niu J, Li H et al (2017) Knee symptomatic osteoarthritis, 
walking disability, NSAIDs use and all-cause mortality: popula-
tion-based Wuchuan osteoarthritis study. Sci Rep 7:3309
 44. Smith D, Wilkie R, Croft P et al (2018) Pain and mortality in 
older adults: the influence of pain phenotype. Arthritis Care Res 
70:236–243
 45. Wilkie R, Parmar SS, Blagojevic-Bucknall M et al (2019) Reasons 
why osteoarthritis predicts mortality: path analysis within a Cox 
proportional hazards model. RMD Open 5:e001048
 46. Cleveland RJ, Alvarez C, Schwartz TA et al (2019) The impact 
of painful knee osteoarthritis on mortality: a community-based 
cohort study with over 24 years of follow-up. Osteoarthritis Cartil 
27:593–602
 47. Castano Betancourt MC, Dehghan A, Campos N et al (2013) 
Osteoarthritis and mortality: meta-analysis of two prospective 
cohorts. Osteoarthritis Cartil 21:S151
 48. van Dijk GM, Veenhof C, Schellevis F et al (2008) Comorbidity, 
limitations in activities and pain in patients with osteoarthritis of 
the hip or knee. BMC Musculoskelet Disord 9:95
 49. Kadam UT, Jordan K, Croft PR (2004) Clinical comorbidity in 
patients with osteoarthritis: a case-control study of general prac-
tice consulters in England and Wales. Ann Rheum Dis 63:408–414
 50. Clynes MA, Jameson KA, Edwards MH et al (2019) Impact of 
osteoarthritis on activities of daily living: does joint site matter? 
Aging Clin Exp Res 31:1049–1056
 51. Cleveland RJ, Alvarez C, Nelson AE et al (2020) Hip symptoms 
are associated with premature mortality: the Johnston County 
Osteoarthritis Project. Osteoarthritis Cartil 28:1330–1340
 52. Schiphof D, Boers M, Bierma-Zeinstra SM (2008) Differences in 
descriptions of Kellgren and Lawrence grades of knee osteoar-
thritis. Ann Rheum Dis 67:1034–1036
 53. Pereira D, Peleteiro B, Araujo J et al (2011) The effect of osteo-
arthritis definition on prevalence and incidence estimates: a sys-
tematic review. Osteoarthritis Cartil 19:1270–1285
 54. Lapane KL, Liu S-H (2016) Commentary: osteoarthritis and mor-
tality: answering questions or questioning answers? Epidemiology 
(Cambridge, Mass) 27:477–478
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
545Aging Clinical and Experimental Research (2021) 33:529–545 
1 3
Authors and Affiliations
Kirsten M. Leyland1,2 · Lucy S. Gates2,3 · Maria T. Sanchez‑Santos4 · Michael C. Nevitt5 · David Felson6 · 
Graeme Jones7 · Joanne M. Jordan8 · Andrew Judge2,9 · Dani Prieto‑Alhambra4 · Noriko Yoshimura10 · 
Julia L. Newton2 · Leigh F. Callahan8 · Cyrus Cooper2,11 · Mark E. Batt12 · Jianhao Lin13 · Qiang Liu13 · 
Rebecca J. Cleveland8 · Gary S. Collins4 · Nigel K. Arden2,11  · The PCCOA Steering Committee
 Lyn March 
 lyn.march@sydney.edu.au
 Gillian Hawker 
 g.hawker@utoronto.ca
 Philip Conaghan 
 P.Conaghan@leeds.ac.uk
 Virginia Byers Kraus 
 kraus004@duke.edu
 Ali Guermazi 
 guermazi@bu.edu
 David Hunter 
 David.Hunter@sydney.edu.au
 Jeffrey N. Katz 
 jnkatz@bwh.harvard.edu
 Tim McAlindon 
 tmcalindon@tuftsmedicalcenter.org
 Tuhina Neogi 
 tneogi@bu.edu
 Lee Simon 
 lssconsult@aol.com
 Marita Cross 
 marita.cross@sydney.edu.au
 Lauren King 
 laurenkarinaking@gmail.com
1 MRC Integrated Epidemiology Unit, Population Health 
Sciences, University of Bristol, Bristol, UK
2 Nuffield Department of Orthopaedics, Rheumatology 
and Musculoskeletal Sciences, University of Oxford, Oxford, 
UK
3 Centre for Sport, Exercise and Osteoarthritis Research Versus 
Arthritis, University of Southampton, Southampton, UK
4 Centre for Statistics in Medicine, Nuffield Department 
of Orthopaedics, Rheumatology and Musculoskeletal 
Sciences, University of Oxford, Oxford, UK
5 Department of Epidemiology and Biostatistics, University 
of California, San Francisco, San Francisco, CA, USA
6 Boston University School of Medicine, Boston, MA, USA
7 Menzies Institute for Medical Research, University 
of Tasmania, Hobart, Australia
8 Department of Medicine, University of North Carolina 
School of Medicine, Chapel Hill, NC, USA
9 Musculoskeletal Research Unit, Translational Health 
Sciences, Bristol Medical School, University of Bristol, 
Bristol, UK
10 Department of Preventive Medicine for Locomotive Organ 
Disorders, 22nd Century Medical and Research Center, The 
University of Tokyo, Tokyo, Japan
11 MRC Lifecourse Epidemiology Unit, University 
of Southampton, Southampton General Hospital, 
Southampton, UK
12 Centre for Sport, Exercise and Osteoarthritis Research Versus 
Arthritis, Nottingham University Hospitals, Nottingham, UK
13 Peking University People’s Hospital, Arthritis Clinic 
and Research Centre, Beijing, China
